12,286 Shares in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Bought by SG Americas Securities LLC

SG Americas Securities LLC bought a new stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 12,286 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 1st quarter worth approximately $1,482,000. Cornercap Investment Counsel Inc. bought a new stake in Inovio Pharmaceuticals in the second quarter worth $184,000. American Century Companies Inc. raised its stake in Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 12,100 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Inovio Pharmaceuticals during the second quarter valued at $661,000. Finally, Signature Estate & Investment Advisors LLC purchased a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth $88,000. 26.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on INO shares. Royal Bank of Canada decreased their target price on shares of Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. HC Wainwright restated a “neutral” rating and set a $15.00 price objective on shares of Inovio Pharmaceuticals in a research report on Monday, July 15th. Finally, Oppenheimer dropped their target price on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $43.80.

Inovio Pharmaceuticals Stock Up 1.3 %

INO stock opened at $5.67 on Tuesday. Inovio Pharmaceuticals, Inc. has a 12 month low of $3.89 and a 12 month high of $14.75. The company has a 50-day moving average price of $6.26 and a 200 day moving average price of $8.67.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. During the same period in the previous year, the business earned ($1.56) EPS. As a group, research analysts forecast that Inovio Pharmaceuticals, Inc. will post -4.64 earnings per share for the current fiscal year.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.